Publications by authors named "Joanna Marie Busoy"
To investigate the correlation between posterior pole choroidal blood flow evaluated with digital subtraction indocyanine green angiography and enface optical coherence tomography angiography (OCTA). Imaging in animal study. The anatomy of 2 cynomogulus monkeys was studied.
View Article and Find Full Text PDFPurpose: To determine the tomographic, angiographic, and histologic changes in the choroid and retina of cynomolgus monkeys after systemic adrenaline and verteporfin photodynamic therapy (vPDT).
Methods: Six cynomolgus monkeys (12 eyes) were treated with vPDT only (n = 2), adrenaline only for eight weeks (n = 2), adrenaline for eight weeks with vPDT at week 4 (n = 4), and adrenaline for 12 weeks and vPDT at week 8 (n = 4). Spectral-domain optical coherence tomography, angiography, and autofluorescence were performed at baseline and every 14 days thereafter until 28 days after adrenaline therapy or vPDT.
To describe patterns of reperfusion in the superficial vascular plexus (SVP), deep capillary plexus (DCP) and choriocapillaris (CC) as detected on optical coherence tomography (OCTA) in cynomogulus macaque monkey model following increase in intraocular pressure by an intravitreal injection. Animal imaging study. Two cynomogulus macaque monkeys.
View Article and Find Full Text PDFArticle Synopsis
- Abnormal blood vessel formation in the eye is a major cause of blindness and targeting this with anti-VEGF treatments has helped, but some patients don't respond well.
- This study investigates the effectiveness of Apratoxin S4, showing that it significantly inhibits the growth and activation of retinal blood vessel cells and works well alongside existing VEGF inhibitors.
- Apratoxin S4 demonstrates strong antiangiogenic effects and targets multiple pathways involved in abnormal blood vessel formation, making it a promising treatment option for ocular diseases.
Anti-vascular endothelial growth factor (VEGF) therapies lead to a major breakthrough in treatment of neovascular retinal diseases such as age-related macular degeneration or diabetic retinopathy. Current management of these conditions require regular and frequent intravitreal injections to prevent disease recurrence once the effect of the injected drug wears off. This has led to a pressing clinical need of developing sustained release formulations or therapies with longer duration.
View Article and Find Full Text PDF